Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer

Nature Clinical Practice Oncology volume 5, pages 76–77 (2008)Cite this article

boxed-textKaufmann M et al. (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25: 2664–2670

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Coombes RC et al. (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559–570

    Article  CAS  Google Scholar 

  2. Jakesz R et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–462

    Article  CAS  Google Scholar 

  3. Boccardo F et al. (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23: 5138–5147

    Article  CAS  Google Scholar 

  4. Jonat W et al. (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7: 991–996

    Article  CAS  Google Scholar 

  5. Boccardo F et al. (2007) Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of two consecutive trials. Cancer 109: 1060–1067

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. University and National Cancer Research Institute of Genoa, Largo Rosanna Benzi10, 16132 Genoa, Italy f.boccardo@unige.it

Authors and Affiliations

  1. F Boccardo is Professor of Medical Oncology and Chairman of the Department of Oncology, Biology and Genetics at the University of Genoa, and Director of the Academic Unit of Medical Oncology (Medical Oncology B) at the National Cancer Research Institute of Genoa, Italy.,

    Francesco Boccardo

Authors
  1. Francesco Boccardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boccardo, F. Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer. Nat Rev Clin Oncol 5, 76–77 (2008). https://doi.org/10.1038/ncponc1015

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1015

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing